Published 16 hours ago • loading... • Updated 16 hours ago

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

On Sunday, Aug. 9, 2026, HanchorBio Inc. announced a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, formalized through a signed memorandum of understanding.
The Taiwan Cancer Moonshot Program has established excellence in cancer proteogenomics and multi-omics research, particularly in Asian cancer populations, connecting these capabilities with HanchorBio's clinical-stage Fc-Based Designer Biologics platform.
"The significance of this strategic collaboration is that it brings TCMP's capabilities directly into the drug-development process," said Scott Liu, PhD, Founder and Chairman of HanchorBio, as the team aims to identify biomarkers and evaluate T-cell functional states.
Together, the parties aim to establish a translational model: PATIENT-DERIVED DISCOVERY, MOLECULAR & IMMUNE INSIGHT, BIOMARKER-GUIDED CLINICAL DEVELOPMENT, and PRECISION IMMUNOTHERAPY to improve treatment response understanding.
This effort builds upon landmark cancer biology studies published in Cell in 2020 and Cancer Cell in 2025, as HanchorBio aims to translate Taiwan-originated scientific innovation into global therapeutic development.

Insights by Ground AI

16 Articles

KULR-TV

+15 Reposted by 15 other sources

Center

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate biomarker-driven drug development and strengthen next-generation precision immunotherapy

16 hours ago·Billings, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year